News
10-03-2010, 04:11 AM
Celsion Corporation (Nasdaq: CLSN) announced that interim data from its Phase I/II DIGNITY trial of ThermoDox® in Recurrent Chest Wall (RCW) Breast Cancer were presented at the poster session at the 2010 Breast Cancer Symposium. The abstract provided updated clinical results from the 40 mg/m2 dose cohort...
More... (http://mnt.to/f/3KGS)
More... (http://mnt.to/f/3KGS)